期刊
ANTIOXIDANTS & REDOX SIGNALING
卷 14, 期 5, 页码 767-775出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2010.3282
关键词
-
资金
- Teva Pharmaceutical Industries Ltd. (Israel)
- H. Lundbeck A/S (Denmark)
- Rappoport Family Research Institute, Technion-Israel Institute of Technology
The anti-Parkinsonian, monoamine oxidase-B inhibitor drug, rasagiline (Azilect (R)), is primarily metabolized by hepatic cytochrome P450 isoenzyme 1A2-mediated N-dealkylation to form its major metabolite, 1-(R)-aminoindan. The present study was undertaken to further investigate, for the first time, the possible neuroprotective effect of 1-(R)-aminoindan in two rat models of Parkinson's disease, the 6-hydroxydopamine- and lactacystin (a proteasomal inhibitor)-induced nigrostriatal degeneration. 1-(R)-aminoindan reversed behavioral asymmetry and restored striatal catecholamine levels in these two rat models and significantly protected neurons from hydrogen peroxide-induced oxidative stress. These observations indicate that 1-(R)-aminoindan may contribute to the overall neuroprotective activity of its parental compound, rasagiline. Antioxid. Redox Signal. 14, 767-775.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据